Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a…
- M. Bazinet, V. Pântea, +11 authors A. Vaillant
- Medicine
- The lancet. Gastroenterology & hepatology
- 1 December 2017
BACKGROUND
REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the restoration of functional control of HBV infection by immunotherapy. We assessed the safety and… Expand
Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection
- Michel Bazinet, V. Pântea, +8 authors A. Vaillant
- Medicine
- 2016
1. Replicor Inc. Montreal, Canada; 2. Department of Infectious Diseases, N. Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; 3. Toma Ciorba Infectious Clinical… Expand
Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month…
- Michel Bazinet, V. Pântea, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, A. Vaillant
- Medicine
- 1 April 2018
REP 2139 is a nucleic acid polymer which blocks the assembly / secretion of HBV subviral particles1 and additionally binds to the small and large forms of HDAg2 (see Fig. 1). In the previous REP 301… Expand
LO2 : Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in caucasian patients with chronic HBV/HDV co-infection
- Michel Bazinet, V. Pântea, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, A. Vaillant
- Medicine
- 1 April 2015
Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian…
- Michel Bazinet, V. Pântea, +10 authors A. Vaillant
- Medicine
- 2017
Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a
- A. Vaillant, Michel Bazinet, +10 authors A. Krawczyk
- Medicine
- 1 April 2018
One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
- Michel Bazinet, V. Pântea, +4 authors A. Vaillant
- Medicine
- 2017
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
- M. Bazinet, V. Pântea, +11 authors A. Vaillant
- Medicine
- Gastroenterology
- 5 March 2020
BACKGROUND & AIMS
Nucleic acid polymers (NAPs) inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles. We performed an open-label, phase 2 study of the safety and efficacy of… Expand
Safety and efficacy of REP 2139 and pegylated interferon alfa-2 a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection ( REP 301 and REP 301-LTF ) : a…
- M. Bazinet, V. Pântea, +11 authors A. Vaillant
- 2017
Replicor, Montreal, QC, Canada (M Bazinet MD, A Vaillant PhD); Department of Infectious Diseases, State University of Medicine and Pharmacy ‘Nicolae Testemitanu’, Chișinău, Moldova (Prof V Pântea MD,… Expand
- 5
- PDF